References
- Park C-W, Lim S-Y, Moon Y-W, et al. Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial. Climacteric. 2021;24(4):408–414.
- Baber RJ, Panay N, Fenton A, IMS Writing Group2016 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
- De Villiers TJ. The role of menopause hormone therapy in the management of osteoporosis. Climacteric. 2015;18(sup2):19–31.
- Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738.
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopause hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231.
- El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular risk: implications for timing of early prevention. Circulation. 2020;22:e506–e532.
- Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in post-menopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291(24):2947–2958.